Mallinckrodt Must Publicize Price Increases In Wake Of DOJ Settlement On Medicaid Rebates
Under corporate integrity agreement, Mallinckrodt must post proposed list price increases for Acthar and other non-generic products along with a link to executive compensation. $234m settlement resolves allegations it underpaid Medicaid rebates resulting from Acthar price hikes.
You may also be interested in...
Public Company Edition: Mallinckrodt entered into a restructuring support agreement with most of its debt holders and will de-list. Also, Aprinoia no longer plans to go public in a SPAC merger and Novartis, Agenus and Aravive revealed job cuts.
Terlivaz is the first product approved to improve kidney function in adults with hepatorenal syndrome (HRS). The approval is a milestone in a long regulatory road for the drug.
After emerging successfully from bankruptcy proceedings, and appointing the thoroughly experienced Siggi Olafsson as its CEO, Mallinckrodt has unveiled a new senior leadership team.